The company’s lead clinical program is based on the principal of blocking or antagonizing select metabotropic glutamate receptors (mGluR), which are associated with a number of CNS diseases. The company’s lead compound, BCI-632 and its prodrug, BCI-838, have been extensively studied in preclinical models for major depressive disorder, treatment resistant depression and potentially Alzheimer’s disease. BCI completed a Phase 1 study for BCI-838 and plans to initiate a proof of concept trial for treatment resistant depression.

BrainCells represents a novel approach to the way CNS drugs are discovered.